Elevance Health, Inc.

NYSE: ELV·Indianapolis, Indiana·

Price
$446.28
Base IV
$430.37

Valuation snapshot

Above base case

At $446.28, the price sits between our base case ($430.37) and bull case ($748.82).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$430.37
96% of the price · range $212.66–$748.82
Price vs base case
4% above
$446.28 against $430.37
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has risen 5.7% since this valuation was struck on 2026-11-01, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $212.66 to bull $748.82. Values per share.

Price against each value

Bear case
$212.66
Price 110% above
No growth
…
—
Base case
$430.37
Price 4% above
Researched bygemini-3.8-flash-medium
Valuation Nov 1, 2026 · Price as of Nov 16, 2026How we got here

What does Elevance Health do?

Elevance Health provides managed care health plans and pharmacy services to individuals and employers, while offering administrative services like claims processing and care management to healthcare organizations.

It brought in $201.8B of sales in the 12 months to Sep 2026.

Led by Gail K. Boudreaux, President and Chief Executive Officer since 2017. Elevance Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024

Industry
Financials
Based in
Indianapolis, Indiana
Trades on
NYSE as ELV

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 3¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 86¢ of every dollar.

  • Sales, marketing and admin11¢
  • Everything else it takes to operate86¢
  • Tax1¢
  • Left as profit3¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Elevance Health, and for what?

Elevance sells health insurance and related services, including pharmacy, behavioral health and complex care support. It earns premiums when it takes on members’ healthcare costs, and fees for administering health plans and providing pharmacy and other health services.

Its customers include individuals, employers, government health programs, federal employees, and other health plans and organizations that buy its administrative, pharmacy or care services.

  • Health Benefits

    Health plans for individuals, employers, Medicare and Medicaid members, plus administration and specialty insurance services. 2025 segment revenue includes premiums and service fees.

  • CarelonRx

    Pharmacy services such as home delivery, specialty pharmacies, prescription claims administration, formulary management and infusion services. 2025 segment revenue includes product revenue and fees.

  • Carelon Services

    Care and health system services, including behavioral health, care management, virtual and home care, provider support, analytics and payment integrity.

  • Corporate & Other

    Smaller businesses and corporate activities that do not meet the threshold for a separate reportable segment.

We don't have each line's share of sales for this company yet.

2025 Form 10-K

How is the business doing?

Sales grew from $121.9B in 2020 to $199.1B in 2025, about 10% a year.

Running the business leaves about 3¢ of each sales dollar as operating profit, down from 5¢ in 2020.

After paying for its upkeep and new investment, it had $6.5B of cash to spare in the 12 months to Sep 2026.

Sales$199.1B
20162025
Operating margin4%
20162025
Free cash flow$3.2B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Elevance says its purpose is to improve the health of humanity.

“improving the health of humanity”

Who We Are

Who is responsible for the plan?

  • Gail K. BoudreauxPresident and Chief Executive Officer

    She oversees enterprise strategy, governance, and operational execution across Elevance Health's health benefits and care services organizations. Elevance Health earns revenue primarily through premiums collected for commercial and government health insurance plans and fees for specialized healthcare services.

  • Felicia NorwoodExecutive Vice President and Chief Health Benefits Officer

    She leads Elevance Health's consolidated Health Benefits organization, directing commercial health plans, Medicare, Medicaid, and federal government solutions. The Health Benefits organization delivers the primary revenue stream for the company through health plan membership premiums paid by employers, individual consumers, and government agencies.

  • Ratnakar LavuExecutive Vice President and Chief Digital and Information Officer

    He directs Elevance Health's enterprise digital strategy, technology infrastructure, consumer-facing applications, and Artificial Intelligence Office. Scalable digital platforms and artificial intelligence automate claims processing and power member mobile tools that support health plan operations and administrative efficiency.

Roles checked November 14, 2026.

What management says it is working on now:

Adjusted diluted earnings per share growth, 2027, from the 2026 earnings baseline
At least 12%
Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
Adjusted diluted earnings per share, 2026
At least $29
Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
Medicaid operating margin, Long term
2%–4%
Elevance Health Q3 2026 Earnings Call
Medicare Advantage operating margin, Long term
3%–5%
Elevance Health Q3 2026 Earnings Call
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 1% more than a year earlier. The year before, quarters averaged 6%.

Its operating margin is about where it was a year ago, 2¢ per sales dollar.

Since Oct 2026 the share price has risen 3%, from $434.13 to $446.28.

Bull $748.82Base $430.37Bear $212.66Oct 22Nov 16 · $446.28
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 22, 2026.

Recently

Coming up

  • December 18, 2026

    Fourth-quarter 2026 dividend payment

    The company declared a dividend of $1.72 per share, payable to shareholders of record on December 4.

    Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
  • December 31, 2027

    CVS pharmacy services agreement term

    CarelonRx’s current agreement for certain pharmacy services runs through the end of 2027. The filing says Elevance may elect a three-year extension in specified circumstances.

    2025 Form 10-K
  • January 2027

    Medicaid margin update

    Management said it expects to provide more detail on the path to Medicaid margin improvement in its January earnings call.

    Elevance Health Q3 2026 Earnings Call

Our own estimate moved too: the base case went from $367.22 to $430.37 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Medical costs may outpace premiums

    If care use, hospital and physician prices, or drug costs rise faster than expected, premiums and government contract rates may not cover the difference during the contract period.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  2. Changes to government programs

    Government agencies set or influence rates and program rules. Lower payments, audits, contract losses or changes to eligibility and benefits could reduce revenue or raise costs.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  3. Member enrollment could fall

    Medicaid eligibility reviews, economic changes, premium increases or loss of contracts could reduce enrollment. The company also has significant business concentrations in several states.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  4. Strong competition

    Health plans and pharmacy providers compete on price, network access, service, quality and technology. If Elevance cannot attract or retain customers and providers, its results could suffer.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  5. Cybersecurity and data protection

    A breach affecting Elevance or a service provider could expose sensitive information, disrupt operations and lead to legal costs, penalties or loss of customers.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  6. Medicare quality ratings

    Medicare plan ratings affect enrollment and eligibility for bonus payments. Lower ratings or changes to the rating system could reduce revenue and make plans less attractive.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  7. Total medical membership dropped from 45.7 million in 2024 to 44.9 million by Q3 2026.

    From our researchWould hit how fast sales growElevance Health Q3 2026 Financial Results

  8. A heavy debt load

    It owes $20.4B more than it holds in cash, about 3.8 years of operating profit.

    From the numbers

Is it a good business?

From 2016 to 2025 it earned between 8% and 12% on the capital invested in it, a median of 10%. Its cost of capital in the latest valuation is 7.4%; returns were above it in every one of the 10 years.

From 2016 to 2025 it earned between 10% and 17% on its shareholders' equity, a median of 14%.

Over 10 years its operating margin ranged from 4¢ to 6¢ per sales dollar, a median of 5¢. Gross margin ran from 89¢ to 98¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital8%
20162025

Cost of capital 7.4%

Return on equity13%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 23%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.7% in a year, so each remaining share owns a slightly bigger slice.

It owes $20.4B more than it holds in cash, about 3.8 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $446.28. Our put its value between $212.66 and $748.82, with $430.37 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $212.66

This scenario envisions prolonged headwinds from government plan membership losses and stubbornly elevated care costs holding future expansion near inflation.

Base case, $430.37

This scenario assumes that post-pandemic Medicaid membership losses level off while regular price adjustments and pharmacy services gradually restore steady mid-single-digit sales gains and balanced profits.

Bull case, $748.82

This scenario assumes that rapid growth in specialized pharmacy and clinical care services propels overall expansion above six percent while disciplined cost control and automated claims processing lift profitability to record highs.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price and our value are close.Price above value: 4%

For Elevance Health to be worth today's $446.28, sales would need to grow about 4.6% a year. We assume 4.0%. Over the last 5 years, sales grew 8.6% a year.

−2%0%+2%+4%+6%+8%+10%We assume 4.0%Price needs 4.6%Past 5 yrs 8.6%

Or, if sales grow 4.0% as we assume, the price works with a profit margin of 4.3% (we assume 4.2%).

Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.

Do you think sales can grow 4.6% a year?

Try your own numbers

We're moderately sure of this range: it scores 65 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $430.37 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.0%
  • Operating margin4.2%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$430.37 -3.6%

Build